L-glutathione

L-Glutathione (Reduced): A Comprehensive Reference

1. Identity and Chemical Characterization

1.1 Chemical Names and Synonyms

Glutathione (GSH) is a tripeptide, γ-L-glutamyl-L-cysteinylglycine, present in all mammalian tissues at 1–10 mM concentrations, with the highest concentration in the liver, and is the most abundant non-protein thiol that defends against oxidative stress. Its molecular formula in reduced form is C₁₀H₁₇N₃O₆S, with a molecular weight of 307.3 g per mole. It is known by numerous synonyms, including Gamma-L-glutamyl-L-cysteinylglycine, GSH, L-glutathione, and N-(N-L-gamma-glutamyl-L-cysteinyl) glycine.

1.2 Structural Features

GSH is formed from glutamate, cysteine, and glycine, but it possesses an unusual peptide bond: the N-terminal glutamate and cysteine residues are linked by the γ-carboxyl group of glutamate, rather than the common α-carboxyl peptide bond found in proteins. This specific bond prevents GSH from being hydrolyzed by most peptidases that cleave at the α-carboxyl peptide bond of N-terminal amino acids.

Glutathione exists in reduced (GSH) and oxidized (GSSG) states. The ratio of reduced glutathione to oxidized glutathione within cells is a measure of cellular oxidative stress, where an increased GSSG-to-GSH ratio is indicative of greater oxidative stress. The oxidized state is converted back to the reduced state by NADPH, a reaction catalyzed by glutathione reductase.

1.3 Natural Occurrence and Dietary Sources

Glutathione is a tripeptide made of the amino acids glutamate, cysteine, and glycine, and it is an antioxidant in plants, animals, fungi, and some bacteria and archaea. Glutathione is widely distributed in nature, including yeast cells, botanical life, and animals. The body makes glutathione on its own from three amino acids: cysteine, glutamate, and glycine; it is also found in small amounts in certain foods, such as spinach, avocados, and asparagus.

Biosynthesis of GSH occurs in the cytosol in a tightly regulated manner. Key determinants of GSH synthesis are the availability of the sulfur amino acid precursor cysteine, and the activity of the rate-limiting enzyme glutamate cysteine ligase (GCL), which is composed of a catalytic (GCLC) and a modifier (GCLM) subunit. The second enzyme of GSH synthesis is GSH synthetase (GS).

1.4 Common Supplemental Forms and Preparations

L-Glutathione is available in multiple forms for supplemental or clinical use. Three commonly used routes for administration of glutathione are parenteral, topical, and oral, and the bioavailability of each route is different. In the United States, glutathione is sold as a non-prescription, over-the-counter dietary supplement, usually available as oral capsules or tablets, commonly in 250 mg, 500 mg, or 1000 mg strengths. Glutathione has been evaluated in clinical trials in various formulations, including oral, IV, topical, intranasal, and nebulized.

Novel delivery systems have been developed to address the bioavailability challenge. A novel formulation of micellar glutathione (LipoMicel®) has been evaluated and compared with standard glutathione and liposomal glutathione (Setria® Glutathione) in clinical settings. Glutathione has received GRAS (Generally Recognized as Safe) status from the FDA for use in food products.

2. Historical Discovery and Scientific Development

2.1 Discovery

Glutathione was discovered in 1888 by de Rey-Pailhade, who initially named it "philothion" from the Greek words meaning "love" and "sulfur," because of its reactivity with sulfur to form hydrogen sulfide. His subsequent studies established the widespread presence of philothion in animal and plant tissues, and led to the conclusion that the compound contained cysteine that can undergo reversible oxidation to a disulfide form in the presence of oxygen.

A compound subsequently accepted to be philothion was extracted from muscle tissue in 1921 by Hopkins, who reported that it was autooxidizable and contained glutamic acid as well as cysteine. In the absence of a definitive composition, he suggested that "provisionally, for easy reference, the name glutathione will perhaps be admissible." Hopkins erroneously classified it as a dipeptide of glutamic acid and cysteine. Hunter and Eagles reported the error in 1927, stating that glutathione was a tripeptide; Hopkins accepted this designation in 1929. Harington and Mead finally described the correct chemical structure of the tripeptide in 1935.

In the same year Hopkins confirmed the tripeptide structure, he was awarded the Nobel Prize for this and other work on vitamins and related nutritional factors. GSH was virtually forgotten for 40 years until in 1969, Kosower and Kosower emphasized the scant GSH research in those days, after which scientific interest dramatically accelerated.

2.2 From Laboratory Molecule to Dietary Supplement

The real breakthrough in understanding L-glutathione's function came in the mid-1950s, when researchers found its role in the enzymatic detoxification of hydrogen peroxide, a harmful byproduct of cellular metabolism. In the 1990s, antioxidant supplements were widely promoted for preventing a variety of diseases, including cancer and heart disease. During this period, oral glutathione became popular as an additional antioxidant supplement.

Glutathione is not a botanical herb with a history of traditional use in the usual sense of herbal medicine. It is a molecule endogenous to virtually all living organisms that was identified and characterized through biochemical science. There is no documented tradition of cultures intentionally administering glutathione as such, as the molecule was unknown to pre-scientific medical systems. Its use as a deliberate supplement is an entirely modern phenomenon arising from 20th-century biochemistry.

3. Key Constituents and Mechanisms of Action

3.1 The Active Compound

The bioactive component of L-glutathione supplements is reduced glutathione (GSH) itself — the tripeptide γ-L-glutamyl-L-cysteinylglycine. GSH is the most important thiol-containing molecule in biology, functioning as a redox buffer, antioxidant, and enzyme cofactor against oxidative stress. The thiol (–SH) group on the cysteine residue is the primary reactive site through which GSH exerts its antioxidant and other biochemical actions.

3.2 Antioxidant and Redox-Buffering Mechanisms

GSH's role as a co-substrate for the selenium-dependent glutathione peroxidase (GPx) has been recognized as the most important mechanism for reduction of hydrogen peroxide (H₂O₂) and lipid hydroperoxides. A family of proteins called peroxiredoxins also catalyzes the reduction of H₂O₂ by GSH and other thiols. GSH is also involved as an antioxidant in the detoxification of products deriving from ROS-promoted oxidation of lipids, such as malonyl dialdehyde and 4-hydroxy-2-nonenal.

The resulting oxidized form of GSH (GSSG), characterized by a disulfide bond between two molecules of GSH, is efficiently reduced back to GSH by the NADPH-dependent catalysis of the flavoenzyme GSH reductase, completing a continuous antioxidant cycle.

3.3 Redox Signaling via S-Glutathionylation

Beyond simple free-radical scavenging, GSH acts as a signaling molecule. The reversibility of protein glutathionylation, catalyzed by glutaredoxin, makes this post-translational modification a likely molecular mechanism by which GSH could act as a redox-dependent signaling molecule, in analogy with protein phosphorylation. Proteins can form reversible mixed disulfides with glutathione. Accumulating evidence suggests that GSH may play important roles in cell signaling, particularly through the reaction of S-glutathionylation — the conjugation of GSH with thiol residues on proteins — and through glutathione S-nitrosothiol (GSNO) formation and their roles in redox signaling.

3.4 Detoxification of Xenobiotics

GSH is vital in the detoxification of xenobiotics and regulates cell proliferation, apoptosis, immune function, and fibrogenesis. GSH constitutes a crucial detoxification system that plays a role in the modification of xenobiotics and in the process used to eliminate potentially hazardous compounds. The glutathione S-transferase (GST) enzyme family conjugates GSH to electrophilic substrates, marking them for excretion.

3.5 Metal Homeostasis

Another, often overlooked, role of GSH is its involvement in the homeostasis of some metals. GSH can interact with certain metals for which the SH group shows high affinity; among those most studied for their impact on health are chromium, cadmium, lead, zinc, copper, and iron.

3.6 Mitochondrial Function

GSH is synthesized in the cytosol and can be transported to the mitochondria via specific carriers in the inner mitochondrial membrane. Currently, three known carriers exist for GSH transport: the 2-ketoglutarate carrier (OGC; SLC25A11), the dicarboxylic acid carrier (DIC; SLC25A10), and SLC25A39. When intracellular levels of reactive oxygen species (ROS) increase, a mild accumulation of ROS induces the production of reducing molecules such as GSH and enhances the detoxification mechanism.

3.7 Additional Biochemical Functions

Additional established functions include: (i) maintaining the essential thiol status of proteins and other molecules; (ii) storage of cysteine reserves both in the cell and for interorgan transfer; (iii) involvement in the metabolism of estrogens, leukotrienes, and prostaglandins; (iv) participation in the reduction of ribonucleotides to deoxyribonucleotides; (v) participation in the maturation of iron-sulfur clusters in proteins; and (vi) copper and iron transfer.

4. Bioavailability: A Critical Issue for Supplementation

The pharmacological challenge central to all clinical evaluation of oral L-glutathione supplementation is absorption. GSH's oral bioavailability is below 1% due to enzymatic degradation and poor gastrointestinal absorption. Due to hydrolysis of the tripeptide by intestinal γ-glutamyltransferase, dietary glutathione is not a major determinant for its increase; results obtained in a study of GSH systemic availability showed that it is not possible to enhance GSH levels to a clinically beneficial extent even by the oral administration of a high single dose of 3 g of GSH.

Due to this tight homeostatic regulation and rapid degradation, previous studies found that standard oral glutathione might not effectively raise systemic levels in healthy individuals, primarily due to low bioavailability. Allen et al. reported no significant differences in glutathione status or oxidative stress biomarkers after 4 weeks of oral glutathione supplementation at 500 mg twice daily. Another study using high doses (3 g) of glutathione administered orally also found similarly unimpressive results.

However, longer-duration trials with appropriate formulations have produced more positive results. The first long-term study on oral glutathione supplementation — a randomized, double-blind, placebo-controlled trial on 54 adults lasting 6 months — demonstrated that oral supplementation can significantly increase the body's own glutathione levels. After three months of the study, the high-dose glutathione subjects had a twofold increase in natural killer cell cytotoxicity, compared to placebo.

Novel formulations have been explored to improve absorption. In vivo results, obtained from 15 healthy volunteers, were in favor of GSH level improvement in blood, showing fast absorption (after 30 and 60 minutes) through oral mucosa after an orobuccal fast-slow release formulation. Observed elevations in whole-blood GSH following LipoMicel® treatment indicate that such a formulation effectively increases circulating and cellular GSH levels, suggesting that the enhanced absorption achieved was sufficient to raise total blood GSH despite rapid cellular uptake and turnover.

There continues to be debate as to the best delivery system, whether oral, sublingual, liposomal, or intravenous.

5. Scientific Evidence by Area of Use

5.1 Skin Pigmentation and Dermatology

The most commercially prominent application of L-glutathione is as a skin-lightening agent. Glutathione, a thiol compound, is one of the regulators of the melanogenic pathway in the human system, and its use for skin lightening is widespread particularly in Southeast Asia. The proposed mechanism involves the shift from the synthesis of dark eumelanin toward lighter pheomelanin via inhibition of tyrosinase activity.

Oral administration: Oral administration shows significant but variable decreases in melanin levels with limited side effects. Three relevant randomized controlled trials (RCTs) have been extracted and assessed: one study opposed glutathione as a skin-whitening agent, while the other two showed significant results only to some parts of the body or to certain age groups. In one notable trial, oral glutathione at 250 mg/day in both reduced and oxidized forms showed various beneficial effects on skin properties and is possibly an antiaging agent, at least in middle-aged female subjects. A separate multicenter RCT in Indonesia found that 83 participants aged between 33 and 50 years completed the study, but reductions in spot ultraviolet, spot polarization, and skin tone were greater in the glutathione supplement group than in the placebo group only in certain subgroups, with differences not reaching statistical significance overall.

Topical administration: Despite its popularity, scientific research on topical glutathione is limited. A PRISMA-guided systematic review using PubMed and MEDLINE found that only five clinical trials met the inclusion criteria, and those studies suggest glutathione may improve hyperpigmentation and provide antioxidant advantages. Topical glutathione shows promise for dermatological applications, but further randomized controlled trials are necessary to fully evaluate its efficacy in hyperpigmentation, transepidermal water loss, skin elasticity, and UV damage.

Intravenous (IV) administration: Despite common use in many Asian countries as a skin-lightening agent, the efficacy of IV glutathione remains unclear due to the lack of human clinical trials evaluating the efficacy. There is no evidence regarding dosing, duration, or need for maintenance treatment. Intravenous glutathione, although having rapid action, is associated with serious safety concerns including anaphylaxis and hepatotoxicity, further aggravated by a lack of standardized dosing protocols.

Overall evidence strength for skin lightening: Clinical trial data in the literature examining the biological effects of glutathione intake for skin pigmentation is fragmented with no clear guidelines for the clinician. As a result, clinicians use arbitrary empirical dosage schedules which lead to inconsistent results. Current evidence supports glutathione's potential as a depigmenting agent but underscores the need for rigorous, large-scale clinical trials to establish long-term safety, optimal dosing, and standardized application. Evidence is therefore rated as preliminary and mixed.

5.2 Liver Disease (NAFLD/NASH)

Non-alcoholic fatty liver disease (NAFLD) is a global cause of liver dysfunction and can progress to severe conditions such as non-alcoholic steatohepatitis (NASH) and cirrhosis due to oxidative stress and sustained cellular injury. Glutathione (GSH), a key antioxidant, has shown promising potential in reducing oxidative stress, maintaining redox balance, and improving liver function.

A pilot clinical study enrolled 15 NAFLD patients (5 with fatty liver, 10 with NASH). Three hundred milligrams per day of glutathione was given orally to patients with NAFLD every day, and an oxidative stress marker and biochemical tests were analyzed before treatment and 1 and 3 months after starting the treatment. This pilot study demonstrated that antioxidant therapy with glutathione may reduce the pathological oxidative stress in the liver in NASH, potentially preventing the progression from NAFLD to NASH.

A literature review covering studies from 2014 to 2024 found that analysis of three studies totaling 109 participants demonstrated consistent improvements in alanine transaminase (ALT) levels and reductions in oxidative stress markers like 8-hydroxy-2-deoxyguanosine (8-OHdG). However, small sample sizes and inconsistent protocols limit generalizability, and further large-scale RCTs are required to confirm GSH's efficacy, determine optimal dosing, and assess long-term effects.

Overall evidence strength for liver disease: Preliminary. Human pilot data is promising but limited by small sample sizes, lack of controls in some studies, and heterogeneous protocols.

5.3 Neurological Disease — Parkinson's Disease

Glutathione has been substantially investigated in Parkinson's disease (PD) because PD is a neurodegenerative disorder in which deficits of the primary intracellular antioxidant, glutathione (GSH), are postulated to mediate increased oxidative stress and mitochondrial dysfunction in the pathogenic cascade leading up to the loss of nigrostriatal dopaminergic neurons that is the hallmark of the disorder.

Sechi et al. administered glutathione intravenously (600 mg twice daily for 30 days) to nine individuals with Parkinson's disease and reported significant improvements, which lasted for 2–4 months even after ceasing the therapy. A subsequent randomized, placebo-controlled, double-blind pilot trial evaluated the safety, tolerability, and preliminary efficacy of intravenous glutathione in PD patients whose motor symptoms were not adequately controlled with their current medication regimen. Subjects were randomly assigned to receive intravenous glutathione 1,400 mg or placebo administered three times a week for 4 weeks. Twenty-one subjects were randomly assigned, 11 to glutathione and 10 to placebo. Glutathione was well tolerated and there were no withdrawals because of adverse events in either group. Reported adverse events were similar in the two groups.

The Michael J. Fox Foundation has noted that early research into intranasal glutathione showed that it is safe, well tolerated, and raises levels of glutathione in the brain as seen on imaging scans; however, an MJFF-funded Phase IIb placebo-controlled trial did show mild benefit but because the placebo group also improved, the significance of these results is unclear.

Overall evidence strength for Parkinson's disease: A number of clinical trials have sought to investigate the effects of GSH treatment for PD; however, the sample size of these studies was small and the clinical evidence is insufficient. To determine if IV glutathione is a truly efficacious symptomatic therapy for Parkinson's, larger, randomized, placebo-controlled trials are needed. Evidence is currently rated as insufficient and preliminary.

5.4 Immune Function

GSH is vital in detoxification of xenobiotics and regulates immune function, and the relationship between glutathione and immune competence has attracted clinical interest. The 6-month randomized, double-blind, placebo-controlled trial in 54 adults referenced above found that oral glutathione supplementation may benefit immune health; after three months, the high-dose glutathione subjects had a twofold increase in natural killer cell cytotoxicity, compared to placebo.

Lower GSH levels in patients with AIDS have been correlated with immune deficiency, and the association between glutathione depletion and impaired immunity has been described across multiple disease states. Changes in GSH levels or deregulation of the redox status are caused by or are at least associated with diverse pathologies, with the most thoroughly investigated cases including cardiovascular and neurodegenerative diseases, cancer, AIDS, cystic fibrosis, liver disorders, diabetes mellitus, and associated complications.

Overall evidence strength for immune modulation: Early human data is suggestive, but the evidence base is limited to small studies; further RCTs are required.

5.5 Cystic Fibrosis and Gastrointestinal Conditions

Glutathione has been studied in cystic fibrosis patients. Decreased glutathione in their intestines can lead to inflammation, pain, decreased absorption of food, weight loss, and growth failure. A 2015 study published in the Journal of Pediatric Gastroenterology and Nutrition found that supplementation with glutathione three times per day with meals has been shown to decrease intestinal inflammation and improve growth in children. This finding is specific to a patient population with established GSH deficiency and should not be generalized to healthy individuals.

5.6 Peripheral Artery Disease

Research has assessed glutathione's effect on people with vascular disease of the arteries that go to the legs. In clinical contexts, intravenous administration is used when rapid glutathione elevation is the clinical goal. The evidence base for peripheral artery disease specifically is limited to small, preliminary trials and cannot currently be considered conclusive.

5.7 Chemotherapy Adjunct

Glutathione has been used as a chemotherapy adjunct (intramuscular and intravenous use) and is considered possibly effective for chemotherapy toxicity. Therapeutically, glutathione is used in medical settings, notably via injection or inhalation, for conditions such as acetaminophen overdose and cystic fibrosis. The use of GSH to reduce nephrotoxicity from platinum-based chemotherapy agents has been the most clinically developed, though evidence remains at the level of individual trials rather than established guideline recommendations.

5.8 Skin Aging and Antioxidant Status

As a skin-whitening agent, studies showed that glutathione yielded other cosmetic benefits, as it may improve skin elasticity and reduce skin wrinkles. Oral glutathione at 250 mg/day in both reduced and oxidized forms showed various beneficial effects on skin properties and is possibly an antiaging agent, at least in middle-aged female subjects. These findings, while encouraging, are drawn from small, short-duration trials and require replication in larger populations.

6. Body Systems Associated with L-Glutathione

• Hepatic system: The highest GSH concentration is found in the liver, which plays a central role in interorgan GSH homeostasis. GSH is essential for hepatic detoxification of drugs, xenobiotics, and reactive metabolites.
• Nervous system: In the brain, dysfunction of GSH synthesis leading to GSH depletion exacerbates oxidative stress, which is linked to the pathogenesis of aging-related neurodegenerative diseases.
• Immune system: GSH is a key determinant of redox signaling, vital in detoxification of xenobiotics, and regulates immune function.
• Skin: As the primary barrier to environmental and metabolic stress, the skin is susceptible to oxidative damage, and the thiol-containing tripeptide glutathione plays a central role in combating it.
• Cardiovascular system: Cardiovascular diseases are among the most thoroughly investigated conditions associated with changes in GSH levels or deregulation of redox status.
• Mitochondria: GSH is synthesized in the cytosol and transported to the mitochondria, where it is critical for protection against mitochondria-derived ROS.
• Respiratory system: Inhaled glutathione has been evaluated in cystic fibrosis and related pulmonary conditions.

7. Dosage Forms and Doses Reported in Studies

The following doses are reported directly from cited sources and are not recommendations:

• Weschawalit et al. administered 250 mg glutathione daily, both reduced GSH and oxidized GSSG forms, to 60 volunteers for 12 weeks, showing a depigmenting effect without adverse effects.
• One study administered 500 mg twice daily for four weeks to 40 healthy adults and showed no significant change in serum glutathione levels.
• Three hundred milligrams per day of glutathione was given orally to NAFLD patients for up to 3 months.
• In the Parkinson's pilot RCT, subjects received intravenous glutathione 1,400 mg administered three times a week for 4 weeks.
• Sechi et al. administered glutathione intravenously at 600 mg twice daily for 30 days in nine Parkinson's patients.
• Allen et al. used 500 mg twice daily for 4 weeks in a study of oral glutathione supplementation.
• A randomized, double-blind, crossover study in healthy adults (n = 14) assessed whole-blood GSH following single oral doses of standard glutathione (500 mg), liposomal glutathione (Setria®), and micellar glutathione (LipoMicel®, 300 mg).
• Standard oral supplement preparations are commonly sold in 250 mg, 500 mg, or 1000 mg capsules or tablets.

8. Safety Considerations and Interactions

8.1 General Tolerability

Glutathione is generally considered a safe ingredient for use as a dietary supplement. An oral acute toxicity study of GSH in mice found that the lethal dose 50 (LD₅₀) was more than 5 g/kg, indicating that glutathione is nontoxic. In many clinical trials, no serious adverse reactions have been observed.

Glutathione was well tolerated in oral preparations, but not in parenteral preparations, where the risk profile is more significant. Most commonly reported side effects in clinical trial data are mild digestive side effects like abdominal discomfort, nausea, vomiting, diarrhea, rash, and appetite loss.

8.2 Intravenous Use and Serious Adverse Effects

Safety data for IV glutathione is inadequate; IV glutathione use has been linked to serious adverse effects such as liver failure, kidney failure, and Stevens-Johnson syndrome, calling into question its safety. Intravenous glutathione is associated with serious safety concerns including anaphylaxis and hepatotoxicity, further aggravated by a lack of standardized dosing protocols.

8.3 Liver Enzyme Elevations

Increases in transaminases occurred in two subjects in one trial, highlighting the fact that blood chemistry should be performed even when individuals are taking over-the-counter supplements. Nonetheless, these adverse events were transient and the blood parameters promptly returned to their normal values upon cessation of consumption.

8.4 Long-Term and High-Dose Risks

High doses of glutathione for prolonged periods may cause chronic toxicity and carry some risks like zinc depletion, hypersensitivity, drug interactions, and potential teratogenicity. Specifically: long-term use of glutathione may lower zinc levels.

8.5 Drug Interactions

The interactions between glutathione and medicines are not fully understood. As with most dietary supplements, the research on drug interactions with glutathione is incomplete. Interactions may occur between the different antioxidants. GSH maintains exogenous antioxidants such as vitamins C and E in their reduced (active antioxidant) forms, which may be pharmacodynamically relevant. Chemotherapy drugs may have altered effectiveness, as antioxidant properties could interfere with treatment mechanisms. Patients using warfarin (blood thinner) may need more frequent blood checks and higher doses to achieve the medication target, according to one clinical trial consent document, though formal pharmacokinetic data on this interaction is limited.

8.6 Regulatory Status

Glutathione is regarded as a food or health supplement in several countries including the Philippines, Malaysia, Taiwan, and Thailand, while it is considered a pharmaceutical agent in Korea, Japan, and the People's Republic of China. Its use is being popularized by the lay press and in some cases there has been excessive usage of glutathione by the public, leading to some national drug control authorities in Southeast Asia restricting its sale and usage. Glutathione has received GRAS status from the FDA for use in food products. The FDA has not reviewed glutathione supplements for safety and effectiveness in the same manner as pharmaceutical drugs.

8.7 Evidence Gaps

Clinical trial data in the literature examining the biological effects of glutathione intake is fragmented with no clear guidelines for clinicians. Efficacy and long-term safety of either the reduced or oxidized form have not been examined systematically, and clinical trial data regarding the effectiveness of glutathione treatment is conflicting or lacking for most medical conditions.

References

• Lu SC. Glutathione Synthesis. Biochimica et Biophysica Acta. PMC3549305, NIH/PMC.
• Deponte M. Glutathione Homeostasis and Functions: Potential Targets for Medical Interventions. Journal of Amino Acids. PMC3303626, NIH/PMC.
• Aquilano K, et al. Glutathione: New roles in redox signaling for an old antioxidant. Frontiers in Pharmacology. PMC4144092, NIH/PMC.
• Ogita K, et al. Glutathione in Cellular Redox Homeostasis: Association with the Excitatory Amino Acid Carrier 1 (EAAC1). Molecules. PMC6272787, NIH/PMC.
• Ribas V, et al. Mitochondrial Glutathione in Cellular Redox Homeostasis and Disease Manifestation. PMC10816320, NIH/PMC.
• Fratelli M, et al. Gene expression profiling reveals a signaling role of glutathione in redox regulation. PMC1236550, NIH/PMC.
• Aquilano K, et al. Natural Compounds and Glutathione: Beyond Mere Antioxidants. Antioxidants. PMC10376414, NIH/PMC.
• Minich DM, Brown BI. Glutathione: A Samsonian life-sustaining small molecule that protects against oxidative stress, ageing and damaging inflammation. Frontiers in Nutrition. PMC9664149, NIH/PMC.
• Minich DM, Brown BI. A Review of Dietary (Phyto)Nutrients for Glutathione Support. Nutrients. PMC6770193, NIH/PMC.
• Randomized Crossover Clinical Trial on Oral Glutathione Bioavailability. Antioxidants. PMC13023597, NIH/PMC.
• Enhancing the Oral Bioavailability of Glutathione Using Innovative Analogue Approaches. PMC11945201, NIH/PMC.
• Bioavailability Study of an Innovative Orobuccal Formulation of Glutathione. PMC4663342, NIH/PMC.
• Augmented Glutathione Absorption from Oral Mucosa and its Effect on Skin Pigmentation: A Clinical Review. PMC9473545, NIH/PMC.
• Systemic Glutathione as a Skin-Whitening Agent in Adults. PMC7196133, NIH/PMC.
• Weschawalit S, et al. Glutathione and its antiaging and antimelanogenic effects. Clinical, Cosmetic and Investigational Dermatology. PMC5413479, NIH/PMC.
• Evaluating Oral Glutathione Plus Ascorbic Acid, Alpha-Lipoic Acid, and Zinc Aspartate as a Skin-Lightening Agent: An Indonesian Multicenter RCT. PMC8570360, NIH/PMC.
• Systematic Review of the Efficacy and Safety of Topical Glutathione in Dermatology. PMC12710870, NIH/PMC.
• Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review. PubMed PMID 40013212.
• Irie M, et al. Reduced Glutathione suppresses Oxidative Stress in Nonalcoholic Fatty Liver Disease. PMC5578552, NIH/PMC.
• A Literature Review of Glutathione Therapy in Ameliorating Hepatic Dysfunction in Non-Alcoholic Fatty Liver Disease. PMC11940638, NIH/PMC.
• Hauser RA, et al. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. PubMed PMID 19230029.
• Ask the MD: Glutathione and Parkinson's. Michael J. Fox Foundation for Parkinson's Research.
• Glutathione as a Biomarker in Parkinson's Disease: Associations with Aging and Disease Severity. PubMed PMID 27446510.
• Glutathione: Uses, Benefits & Dosage — Drugs.com Natural Products Database.
• Glutathione as a Therapeutic Supplement. EBSCO Research Starters: Health and Medicine.
• Glutathione — PubChem CID 124886. National Library of Medicine / NIH.
• Ask the Doctors: What do glutathione supplements do? UCLA Health.
• Glutathione (Plants). PMC3267239, NIH/PMC.
• Perjési P. Preface to the Special Issue "Glutathione: Chemistry and Biochemistry." Molecules. PMC10460063, NIH/PMC.